Tumor Lysis Syndrome in a Patient With Metastatic Endometrial Cancer Treated With Lattice Stereotactic Body Radiation Therapy

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Spatially fractionated radiation therapy: a critical review on current status of clinical and preclinical studies and knowledge gaps

“…SFRT with palliative intent was reported to be well-tolerated. The percentage of grade 3 or higher adverse events (including bleeding (head and neck target), mucositis, small bowel obstruction, and grade 5 tumor lysis syndrome (Schiff et al 2022)) are reported to range from 0% to 24% (Mohiuddin et al 1990, Mohiuddin et al 1999, Neuner et al 2012, Amendola et al 2019, Choi et al 2019, Mohiuddin et al 2020, Ferini et al 2021. A recent published study (Ahmed et al 2023) reports on a large cohort of 53 sarcoma patients treated with SFRT and followed by a conventional radiation therapy with palliative intent in more than 80% of the cases.…”

Palliative Radiotherapy Induced Severe Tumor Lysis Syndrome in a Patient With Multiple Myeloma With Skin Involvement: A Case Report and Review of Literature

“…Table II shows the available reports on RT-induced TLS (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). Two studies reported three cases of RT-induced TLS in MM (19,20).…”

CE: Tumor Lysis Syndrome: An Oncologic Emergency

“…Besides cytotoxic chemotherapy, other cancer treatments can put patients at risk for tumor lysis syndrome. These include radiation; corticosteroids; biologic agents, such as monoclonal antibodies; proteasome inhibitors; targeted therapies, such as tyrosine kinase inhibitors; immunotherapies; and proapoptotic agents, such as lenalidomide 3, 22, 25-27…”

“…Patient characteristics associated with tumor lysis syndrome risk: • male sex 5 • advanced age 5 such as monoclonal antibodies; proteasome inhibitors; targeted therapies, such as tyrosine kinase inhibitors; immunotherapies; and proapoptotic agents, such as lenalidomide. 3,22,[25][26][27]…”